Tag: NSCLC
Clinical Trial with Investigational Potential First-in-class HER3-targeting Antibody-drug Conjugate
A first patient has been dosed in a phase I study evaluating the safety and tolerability of U3-1402, in patients with metastatic or unresectable...
AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...
A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...
Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...
Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...
Immune Checkpoint Inhibitor Nivolumab: Five-year Survival Rate in Advanced Lung Cancer
Data from a phase I clincal trial presented at the Annual Meeting of American Association for Cancer Research (AACR), beimg held April 1-5, 2017...
Mersana’s XMT-1536 Demonstrates Anti-tumor Activity in Lung Cancer Patient-Derived Xenograft Studies
Encouraging data from preclinical studies presented at the 2016 IASLC 17th World Conference on Lung Cancer, in Vienna, Austria, suggests that Mersana Therapeutics' immunoconjugate XMT-1536...
Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...
Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...
XMT-1536 Demonstrates Anti-Cancer Activity in Patients with NaPi2b-expressing Tumors
Preclinical data for Mersana Therapeutics' new immunoconjugate product candidate, XMT-1536, demonstrated significant anti-cancer activity in non-small cell lung cancer (NSCLC) and ovarian cancer tumor models.
The...
Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results
Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...
Novel Targeted Lung Cancer Therapies are Expected to Replace Current Conventional...
Lung cancer, which is mostly a disease of the elderly*, is defined as the uncontrolled growth of abnormal cells in one or both lungs. Approximately 60%...
Companion Diagnostics: Paving the Way for Personalized Medicine
There has been a real revolution in the understanding of molecular biology. This revolution is fueled by the rapid decline in the costs of...
